Thesis
BLA filed on novel surrogate endpoint for fatal orphan disease; FDA acceptance of skin frataxin as the surrogate determines whether approval follows
Larimar submitted a rolling BLA for nomlabofusp, a frataxin protein-replacement fusion for Friedreich's ataxia, a progressive neurological disease with no approved cure, under accelerated approval using skin frataxin as a novel surrogate endpoint FDA has not previously recognized. Approval hinges on whether FDA grants accelerated approval on that surrogate, with open-label data showing 100% of evaluable participants reaching asymptomatic-carrier frataxin levels and directional mFARS benefit versus a natural history reference. The critical risk is the novel, unvalidated surrogate: a single-arm BLA without a randomized efficacy trial is an unusual approval path, and cash runway extends only to Q3 2027, leaving minimal buffer if the review extends or requires additional data.
Focus
FDA approval decision for nomlabofusp
H1 2027
Bull
FDA grants accelerated approval of nomlabofusp based on skin frataxin as a reasonably likely surrogate endpoint, supported by the open-label data showing 82–100% of participants achieving frataxin levels comparable to asymptomatic carriers and directional mFARS improvements versus the FACOMS natural history reference population. This would make nomlabofusp the first approved therapy for Friedreich's ataxia addressing frataxin replacement directly, unlocking U.S. commercialization in a rare, fatal, and currently treatment-limited orphan disease.
Bear
FDA declines to accept skin frataxin as a surrogate endpoint that is reasonably likely to predict clinical benefit, citing the absence of a randomized controlled trial demonstrating that frataxin restoration translates to meaningful functional outcomes — the most likely failure mode given the novel and unvalidated nature of the surrogate. Alternatively, FDA could issue a Complete Response Letter citing manufacturing deficiencies, inadequate characterization of the anaphylaxis risk observed in 10 of 43 participants, or insufficient exposure-response data to support the accelerated approval pathway.
Unlock the full thesis for LRMR.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.